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TO THE EDITOR
Netherton syndrome (NS) is a severe
autosomal recessive skin disorder
caused by mutations in serine protease
inhibitor Kazal-type 5 (SPINK5), which
encodes the lymphoepithelial Kazal-
type-related inhibitor (LEKTI) (Chavanas
et al., 2000). Lack of LEKTI causes
stratum corneum detachment second-
ary to the hyperactivity of epidermal
proteases, which leads to skin barrier
defect, thus facilitating allergen pene-
tration and contributing to atopy in NS.
Affected individuals have chronic and
severe skin inflammation and allergic
manifestations, including atopic derma-
titis–like lesions and elevated serum IgE
levels. Recent studies have shown
that thymic stromal lymphopoietin
(TSLP) and tumor necrosis factor-alpha
(TNF-a) are overexpressed in the LEKTI-
deficient epidermis of NS patients and
SPINK5-null mice (Briot et al., 2009).
This is due to unrestricted activity of
epidermal proteases, including kallik-
rein 5, which activates PAR2 signaling
in keratinocytes, leading to NF-kB
activation and TSLP expression (Briot
et al., 2010). TSLP is produced
by keratinocytes as well as airway
epithelial cells and is necessary and
sufficient for inducing atopic response
in mice (Yoo et al., 2005; Li al., 2006).
It regulates innate immunity and po-
larizes T cells toward a T helper type 2
(Th2) phenotype through the condi-
tioning of antigen-presenting cells
(Soumelis et al., 2002; Soumelis and
Liu, 2004). TNF-a and IL-1 (Lee and
Ziegler, 2007) induce expression of
TSLP, which can synergize with these
pro-inflammatory cytokines to amplify
pro-Th2 cytokine secretion by activated
mast cells (Allakhverdi et al., 2007).
These data suggest that a therapeutic
approach targeting these key molecules
could reduce skin inflammation in NS.
The data and procedures reported in
this article were in accordance with
the institutional ethical requirements of
the University Hospital of Geneva,
Switzerland. The study was conducted
in adherence with the Declaration of
Helsinki Principles. Written informed
consent was obtained from the patient,
a 25-year-old woman who consulted
for an extensive pruritic dermatitis that
had been evolving since birth and was
associated with ichthyosis, asthma,
food allergies, and high levels of IgE
(3, 660 kU l1). The recurrent, severe
inflammatory flares were unresponsive
to systemic dapsone, topical steroids,
tacrolimus, and pimecrolimus. The pre-
sence of diffuse xerosis, a pattern of
ichthyosis circumflexa (Figure 1a), and
outbreaks of severe vesicular and pust-
ular lesions led to the diagnosis of NS,
which was supported by the absence of
epidermal LEKTI detection (Figure 1c,
d). SPINK5 molecular analysis identified
a homozygous mutation leading to a
premature termination codon in exon
12, thus confirming the diagnosis of NS.
Histological analysis of skin sections
revealed an acanthotic and spongiotic
epidermis with subcorneal accumu-
lation of neutrophils (Figure 1e).
A lymphohistiocytic infiltrate with neu-
trophils and eosinophils was present in
the superficial dermis, whereas the
density of mast cells was similar to that
in normal skin. Because TNF-a is
critical for neutrophil skin emigration
(Groves et al., 1995) and skin mast cell
Abbreviations: LEKT1, lymphoepithelial Kazal-type-related inhibitor; NS, Netherton syndrome; SPINK5,
serine protease inhibitor Kazal-type 5; Th2, T helper type 2; TNF-a, tumor necrosis factor-a; TSLP, thymic
stromal lymphopoietin
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activation (van Overveld et al., 1991),
we treated the patient with anti-TNF.
Infliximab infusions at a dose of
5 mg kg1 were given in weeks 0–2–6
and continued every other month.
Clinical improvement was observed after
the second infusion (data not shown).
After 12 infusions (Figure 1b), the skin
was consistently clear of inflammatory
lesions, although xerosis, ichthyosis, and
serum IgE levels were not improved.
Histopathological examination showed a
reduced inflammatory infiltrate with no
change in the density of mast cells
(Figure 1f). The treatment was well
tolerated, and no infection occurred
during the 2-year observation period.
Cytokine expression was assessed in
nonlesional (Figure 2a) and lesional
(Figure 2b) skin by quantitative
real-time PCR. The pro-Th2 cytokines
IL-4, IL-5, and IL-31 were not detected.
IFN-g, IL-10, IL-17, IL-6, IL-8, and IL-23
were exclusively found in lesional skin,
TNF-a, TGF-b (transforming growth
factor-b), and TSLP were present in
both lesional and nonlesional skin
(Figure 2a and b). Reminiscent of
previous studies showing that in NS
keratinocytes are the major source of
TNF-a and TSLP (Briot et al., 2009), our
results indicated that primary culture
of keratinocytes from the patient
(NSK) overexpressed pro-inflammatory
(TNF-a, IL-8, IL-1b, and ICAM-1) and
pro-Th2 (TSLP) molecules when com-
pared with cells from a normal subject
(NHK) (Figure 2c). The 15-fold increase
of TNF-a expression supports the
relevance of infliximab therapy. The
expression of IFN-g, IL-17, IL-23, IL-6,
IL-8, TGF-b, and TSLP in lesional skin
was reduced after 1 year of therapy,
whereas expression of IL-10 and TNF-a
was increased (Figure 2b). In nonle-
sional skin, TGF-b and TSLP expression
was decreased, whereas no change
was observed for TNF-a (Figure 2a).
TSLP protein, which was detected in
the patient’s skin before therapy, was
reduced by fourfold in both lesional
and nonlesional skin after 1 year of
infliximab therapy (Figure 2d). Interest-
ingly, systemic immune response also
appeared to be altered by infliximab.
The blood levels of IL-6 and IL-8 were
reduced after 2 years of infliximab
therapy, whereas the levels of circulat-
ing TNF-a were unaffected (Figure 2e).
In activated peripheral blood mono-
nuclear cells isolated from the patient
after 2 years of therapy, the transcripts
of IL-1, IL-6, IL-4, IL-5, IL-9, and IL-13
were reduced when compared with
those of cells from the healthy control.
In contrast, the Th1 cytokine IFN-g was
overexpressed (Figure 2f), whereas the
pro-inflammatory cytokines IL-17 and
TNF-a showed no significant difference
(Figure 2f).
The KLK5–PAR2–TSLP molecular
pathway is critical for initiating atopic
dermatitis–like lesions in NS, whereas
stratum corneum detachment induces
secondary skin inflammation (Briot
et al., 2010). In our patient, similar to
the subjects in previous studies (Briot
et al., 2009), we found elevated TNF-a,
IL-8, and TSLP expression in cultured
keratinocytes, in the skin and in serum.
The decrease of TSLP, IL-6, and IL-8
expression in the patient’s skin follow-
ing infliximab infusions was associated
with an impressive and prolonged
improvement of the cutaneous rash.
This supports a critical role for TNF-a
and TSLP in NS atopic dermatitis–like
manifestations. Because infliximab is a
neutralizing antibody, downregulation
of TNF-a target genes rather than TNF-a
itself was expected. We found no
decrease in TNF-a in the skin, whereas
TSLP and IL-6 were reduced after 2
years of therapy. Since TNF-a modu-
lates IL-6 and TSLP production
in various tissues, including the skin
(Bogiatzi et al., 2007; He and Geha,
2010), the decrease in circulating cyto-
kines could be attributed to the neu-
tralizing activity of infliximab. Clinical
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Figure 1. Clinical and histological features of Netherton syndrome. (a) Clinical photograph of the back
showing characteristic ichthyosis linearis circumflexa with polycyclic erythematous patches surrounded
by a serpiginous overlying double-edged scale (enlargement). (b) Clinical evolution of skin lesions after 12
infusions of 5 mg kg1 infliximab. Immunostaining of LEKTI in (c) normal human skin and (d) the patient’s
skin. Histopathological images from the patient’s skin (e) before and (f) after 12 infusions of infliximab.
Note the reduced inflammatory infiltrate and the absence of subcorneal pustule in panel f. Bar¼ 40mm.
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improvement was associated with low
expression of Th2 cytokines by acti-
vated peripheral blood mononuclear
cells, whereas IFN-g was enhanced.
Because TSLP is necessary to induce a
Th2-biased response in mice (Yoo et al.,
2005), the decrease of TSLP expression
in the skin might have led to a shift of
the Th2 systemic immune response
toward a Th1 profile. To the best of
our knowledge, there have been no
previous reports showing that anti-TNF
therapy is a promising therapeutic
option for treating this severe inflam-
matory skin disease.
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Figure 2. Modulation of immune response by infliximab in Netherton syndrome. Relative RNA expression of indicated cytokines in (a) nonlesional and
(b) lesional skin of the patient. The results are shown as mean values±SEM. (c) Quantitative real-time RT-PCR (qRT-PCR) analysis of cultured primary keratinocytes
from the healthy control (NHK) and the patient (NSK). Data are shown as mean values of two independent cultures tested in triplicate. (d) Protein expression of thymic
stromal lymphopoietin (TSLP; ELISA, R&D Systems, Minneapolis, MN) in the patient’s skin. (e) Expression of circulating cytokines in the patient’s serum. TSLP was not
detectable after 2 years of infliximab. Reference range: tumor necrosis factor-alpha (TNF-a)o4 pgml1; IL-6o1.5 pgml1; IL-8o90pgml1; TSLP not detectable.
Dotted lines: reference ranges. (f) Relative RNA expression of indicated cytokines in phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs)
isolated from healthy control and patient blood samples. The results are shown as mean values of two independent qRT-PCRs tested in duplicate. Normalization:
(a, b) d-aminolevulinic acid synthase 1, eukaryotic translation elongation factor 1-alpha 1; (c) hypoxanthine-guanine phosphoribosyltransferase; (f) CD3-epsilon.
ICAM-1, intercellular adhesion molecule 1; mRNA, messenger RNA; RU, relative units; TGF-b, transforming growth factor-b.
www.jidonline.org 1949
L Fontao et al.
Infliximab Infusions for Netherton Syndrome
Lionel Fontao1,8, Emmanuel Laffitte1,8,
Anais Briot 2,8, Gu¨rkan Kaya1,
Pascale Roux-Lombard 3,
Sylvie Fraitag4, Alain A. Hovnanian5,6,7
and Jean-Hilaire Saurat1
1Clinic of Dermatology, Geneva University
Hospital, Geneva, Switzerland; 2INSERM,
U563, Toulouse, France; 3Immunology and
Allergy, Department of Internal Medicine,
Geneva University Hospital, Geneva,
Switzerland; 4Department of Pathology, CHU
Necker for Sick Children, APHP, Paris, France;
5INSERM, U781, Paris, France; 6Universite´
Paris V Rene´ Descartes, Paris, France and
7Department of Dermatology and Department
of Genetics, CHU Necker for Sick Children,
Paris, France
E-mail: lionel.fontao@hcuge.ch
8These authors contributed equally to this work.
REFERENCES
Allakhverdi Z, Comeau MR, Jessup HK et al. (2007)
Thymic stromal lymphopoietin is released
by human epithelial cells in response to
microbes, trauma, or inflammation and potently
activates mast cells. J Exp Med 204:253–8
Bogiatzi SI, Fernandez I, Bichet JC et al. (2007)
Cutting edge: proinflammatory and Th2
cytokines synergize to induce thymic stromal
lymphopoietin production by human skin
keratinocytes. J Immunol 178:3373–7
Briot A, Deraison C, Lacroix M et al. (2009)
Kallikrein 5 induces atopic dermatitis-like
lesions through PAR2-mediated thymic stro-
mal lymphopoietin expression in Netherton
syndrome. J Exp Med 206:1135–47
Briot A, Lacroix M, Robin A et al. (2010) Par2
inactivation inhibits early production
of TSLP, but not cutaneous inflammation, in
Netherton syndrome adult mouse model.
J Invest Dermatol 130:2736–42
Chavanas S, Bodemer C, Rochat A et al. (2000)
Mutations in SPINK5, encoding a serine
protease inhibitor, cause Netherton syn-
drome. Nat Genet 25:141–2
Groves RW, Allen MH, Ross EL et al. (1995)
Tumour necrosis factor alpha is pro-inflam-
matory in normal human skin and modulates
cutaneous adhesion molecule expression.
Br J Dermatol 132:345–52
He R, Geha RS (2010) Thymic stromal lympho-
poietin. Ann N Y Acad Sci 1183:13–24
Lee HC, Ziegler SF (2007) Inducible expression of
the proallergic cytokine thymic stromal
lymphopoietin in airway epithelial cells is
controlled by NFkappaB. Proc Natl Acad Sci
USA 104:914–9
Li M, Hener P, Zhang Z et al. (2006) Topical
vitamin D3 and low-calcemic analogs in-
duce thymic stromal lymphopoietin in mouse
keratinocytes and trigger an atopic dermati-
tis. Proc Natl Acad Sci USA 103:11736–41
Soumelis V, Liu YJ (2004) Human thymic stromal
lymphopoietin: a novel epithelial cell-de-
rived cytokine and a potential key player in
the induction of allergic inflammation.
Springer Semin Immunopathol 25:325–33
Soumelis V, Reche PA, Kanzler H et al. (2002)
Human epithelial cells trigger dendritic cell
mediated allergic inflammation by producing
TSLP. Nat Immunol 3:673–80
van Overveld FJ, Jorens PG, Rampart M et al.
(1991) Tumour necrosis factor stimulates
human skin mast cells to release histamine
and tryptase. Clin Exp Allergy 21:711–4
Yoo J, Omori M, Gyarmati D et al. (2005)
Spontaneous atopic dermatitis in mice ex-
pressing an inducible thymic stromal lym-
phopoietin transgene specifically in the skin.
J Exp Med 202:541–9
Migration of Immunocytes across the Basement
Membrane in Skin: The Role of Basement Membrane Pores
Journal of Investigative Dermatology (2011) 131, 1950–1953; doi:10.1038/jid.2011.146; published online 2 June 2011
TO THE EDITOR
The skin basement membrane (BM)
forms a barrier between epidermis and
dermis but allows immunocytes to
migrate through it. Although Langer-
hans cells (LCs) use matrix metallopro-
teinases to exit the epidermis (Noirey
et al., 2002; Ratzinger et al., 2002), it
seems likely that a mechanism exists
to facilitate LC passage through the
BM without the need to generate new
holes in the membrane on each occa-
sion. In lung, eye, and gastrointestinal
tract, BM pores have been described,
which enable immunocyte migration
through this structure (Mahida et al.,
1997; Scott et al., 1997; Howat et al.,
2001). Focal absence of cutaneous
BM was observed by transmission
electron microscopy (TEM) in one study
when murine LCs were adjacent to BM,
but it is unknown whether pores al-
ready existed or were generated de
novo by the LCs (Stoitzner et al.,
2002). Therefore, we investigated
whether BM pores exist in skin and
whether immunocytes use these pores
to traverse the BM.
Immunofluorescence microscopy of
dermis, denuded of epidermis by EDTA
and stained for type-IV collagen (see
Supplementary Materials and Methods
online), from human (n¼17 indivi-
duals) and hairless mouse skin (n¼12
mice) showed uniform staining for
collagen-IV, indicating that the lamina
densa (LD) component of BM covering
the dermis remained intact following
removal of epidermis (data not shown).
A confluent collagen-IV pattern was
similarly noted following epidermis
removal with dispase (n¼4) and NaCl
(n¼2). Scanning electron microscopy
(SEM) of human dermis, denuded
of epidermis, revealed an uneven
coral-like appearance on the upper
parts of dermal papillae, however,
bases of dermal papillae and valleys
between papillae were relatively
smooth; therefore, investigations for
pores focussed on these sites. Small
BM pores were seen, randomly distrib-
uted, on the dermal surface in all
normal skin samples (n¼27 subjects;
23–69 years old) (Figure 1a, b and d).
Mean pore diameter (MPD) was
0.79 mm (measured across 144 pores,
n¼6 samples), 95% CI 0.74–0.84 mm,
range 0.25–2.04 mm, and SD 0.30 mm.
Based on counting 1,806 pores, there
were 28.0 103 pores per mm2 BM,
with average distance between adja-
cent pores of 4.25 mm. Thus, there were
Abbreviations: BM, basement membrane; DNCB, dinitrochlorobenzene; LC, Langerhans cell; LD, lamina
densa; MPD, mean pore diameter; TEM, transmission electron microscopy
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